The objective of the Center is to integrate nanotechnology-based diagnostic and therapeutic tools for comprehensive cancer care. Through the four inter-related projects described in this application we envision a cancer nanomedicine clinic incorporating nanotechnology-based solutions for diagnosis, therapy, and post-therapy monitoring. Advances in cancer nanomedicine provide tremendous potential to improve clinical practice. We hypothesize that combining improved in vitro assays (Project 1) with targeted chemotherapy (Projects 2 and 4) and immunotherapy (Project 3) we can establish a new paradigm in cancer nanomedicine. The novel in vitro assay (Project 1) will be used for both diagnosis and for post-therapy monitoring (Projects 2, 3, and 4). Our overall objective is to demonstrate that nanotechnology-based tools can be integrated for comprehensive cancer care. We focus on two high mortality rate cancers: lung and pancreas. The underlying nanotechnology focus of the center is on novel nanoparticles. The Nanoparticle Engineering Core and the Validation Core will link the projects, providing support for nanoparticle synthesis, surface engineering, new targeting strategies, and toxicology studies. There is considerable overlap in the technology requirements in the four projects, allowing the cores to focus on a limited number of key platforms. The Bioinformatics and Data Sharing Core will provide biostatistics support to the projects and will establish mechanisms for data sharing and data management.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA151838-02
Application #
8133492
Study Section
Special Emphasis Panel (ZCA1-GRB-S (M1))
Program Officer
Grodzinski, Piotr
Project Start
2010-08-25
Project End
2015-07-31
Budget Start
2011-08-01
Budget End
2012-07-31
Support Year
2
Fiscal Year
2011
Total Cost
$2,594,165
Indirect Cost
Name
Johns Hopkins University
Department
Engineering (All Types)
Type
Schools of Engineering
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Russell, Luisa M; Hultz, Margot; Searson, Peter C (2018) Leakage kinetics of the liposomal chemotherapeutic agent Doxil: The role of dissolution, protonation, and passive transport, and implications for mechanism of action. J Control Release 269:171-176
Woodard, Lauren E; Dennis, Cindi L; Borchers, Julie A et al. (2018) Nanoparticle architecture preserves magnetic properties during coating to enable robust multi-modal functionality. Sci Rep 8:12706
Pisanic 2nd, Thomas R; Athamanolap, Pornpat; Wang, Tza-Huei (2017) Defining, distinguishing and detecting the contribution of heterogeneous methylation to cancer heterogeneity. Semin Cell Dev Biol 64:5-17
Liu, Guanshu; Ray Banerjee, Sangeeta; Yang, Xing et al. (2017) A dextran-based probe for the targeted magnetic resonance imaging of tumours expressing prostate-specific membrane antigen. Nat Biomed Eng 1:977-982
Huang, Xinglu; Chisholm, Jane; Zhuang, Jie et al. (2017) Protein nanocages that penetrate airway mucus and tumor tissue. Proc Natl Acad Sci U S A 114:E6595-E6602
Dawidczyk, Charlene M; Russell, Luisa M; Hultz, Margot et al. (2017) Tumor accumulation of liposomal doxorubicin in three murine models: Optimizing delivery efficiency. Nanomedicine 13:1637-1644
Wu, Juan; Qu, Wei; Williford, John-Michael et al. (2017) Improved siRNA delivery efficiency via solvent-induced condensation of micellar nanoparticles. Nanotechnology 28:204002
Schneider, Craig S; Xu, Qingguo; Boylan, Nicholas J et al. (2017) Nanoparticles that do not adhere to mucus provide uniform and long-lasting drug delivery to airways following inhalation. Sci Adv 3:e1601556
Banerjee, Sangeeta R; Foss, Catherine A; Horhota, Allen et al. (2017) 111In- and IRDye800CW-Labeled PLA-PEG Nanoparticle for Imaging Prostate-Specific Membrane Antigen-Expressing Tissues. Biomacromolecules 18:201-209
Shin, Soo Hyun; Kadayakkara, Deepak K; Bulte, Jeff W M (2017) In Vivo (19)F MR Imaging Cell Tracking of Inflammatory Macrophages and Site-specific Development of Colitis-associated Dysplasia. Radiology 282:194-201

Showing the most recent 10 out of 123 publications